Abiopharma

News list

(63% Neutral) REPLIGEN CORP (RGEN) Files Form 8-K

Full text

News bot Jan. 6, 2026, 12:34 p.m.
📋 REPLIGEN CORP (RGEN) - Other Event

Filing Date: 2026-01-06

Accepted: 2026-01-06 07:32:26

Event Type: Other Event

Event Details:

Repligen Corporation (RGEN) Provides Business Update Repligen Corporation (RGEN) issued a business update covering recent developments.
🔍 Detailed Event Analysis:
AI Summary: Executive chair tony hunt to retire; Dr. martin D. MadAus elected chair. Hunt will continue to serve as an advisor to Repligen through March 2027. “He left a strong foundation for us to build upon,” said Olivier Loeillot, Repligen President and CEO.
Key Elements Identified:
Drugs/Compounds: foundation, positioned, Tony
Diseases/Conditions: success, us to build upon
Organizations: Board, Chair of the Board, Martin
💼 Business Developments:
- Partnership: Not available
- Acquisition
- Licensing: Not available
- Regulatory Approval: Not available
- Executive Changes: Not available
Structured Data:
- Company Name: Repligen Corporation
- CIK: 0000730272
- Ticker Symbol: RGEN
- Period End Date: 2026-01-06
- Document Type: 8-K